Identification of novel contributors to retinitis pigmentosa using metabolic and proteomic approaches

使用代谢和蛋白质组学方法鉴定视网膜色素变性的新因素

• 批准号: 10298716
• 负责人: Ellen Ruth Weiss
• 金额: $ 57.74万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10298716
• 关键词: Affect; Anabolism; Blindness; Carnitine; Cell Death; Cell Nucleus; Cessation of life; Coenzyme A; Complete Blindness; Computer Analysis; Computer software; Cone; Critiques; Cyclic GMP; DNA copy number; Data; Data Analyses; Defect; Disease; Disease Progression; Enzymes; Evaluation; Event; Exhibits; Face; Female; Gender; Genes; Genetic; Genetic Diseases; Genetic Models; Goals; Health; Human; Impairment; In Situ Nick-End Labeling; Individual; Inflammation; Lead; Libraries; Light; Link; Mass Spectrum Analysis; Membrane; Metabolic; Metabolic dysfunction; Methods; Mitochondria; Mitochondrial DNA; Modeling; Molecular; Mus; Mutation; Nuclear; Other Genetics; Oxidative Stress; Oxygen Consumption; Paper; Pathway Analysis; Pathway interactions; Periodicity; Photoreceptors; Post-Translational Protein Processing; Process; Proteins; Proteomics; Publishing; Reactive Oxygen Species; Reagent; Reporting; Research; Resolution; Retina; Retinal Cone; Retinal Degeneration; Retinitis Pigmentosa; Rod; Scanning Electron Microscopy; Severity of illness; Stains; Structure; Testing; Therapeutic; Time; Western Blotting; Wild Type Mouse; base; dark rearing; experimental study; genomic locus; immunocytochemistry; male; metabolome; metabolomics; mitochondrial dysfunction; mouse model; mutant; new therapeutic target; non-genetic; novel; novel strategies; phosphodiesterase 6; phosphoric diester hydrolase; photoreceptor degeneration; protein expression; response; retinal rods; targeted treatment; therapeutic target

ABSTRACT Retinitis pigmentosa (RP) is a progressive form of retinal degeneration caused by at least 3,000 mutations in 70 different genes that result in the death of rods, followed by cones, and ultimately blindness. Although oxidative stress and inflammation are observed in RP, early molecular mechanisms in disease progression are unknown. We propose to compare a genetic mouse model of RP, rd10, with wild type mice to determine key pathways that suggest therapeutic targets for treating retinal degeneration utilizing a novel strategy of broad-spectrum metabolomics integrated with proteomics and mitochondrial dysfunction analysis. The rd10 mouse has a mutation in the β subunit of phosphodiesterase 6 (PDE6), which hydrolyzes cGMP in response to light as part of the photoresponse. Mutations in this gene cause recessive RP in humans. Our recent untargeted metabolomics study found abnormal increases in the levels of several deoxypyrimidines and deoxypurines, as well as a key metabolite in the Coenzyme A synthesis pathway, in rd10 compared to wild type mice. These changes were observed at P18, which is when cell death and reduced photoreceptor function are first detected. We hypothesize that the observed changes in the metabolome in rd10 mice are due to changes in the activities of the related proteins/enzymes. To identify changes in the metabolome that occur before reduced photoreceptor function and cell death are detected, we propose to analyze mice at the earlier timepoint, P14. In Specific Aim 1, we will use broad spectrum (untargeted) at P14 and targeted metabolomics at both P14 and P18. In Specific Aim 2, untargeted proteomics will be used to identify proteins/enzymes in membrane, soluble and mitochondrial fractions that may be linked to the disease process. This will be followed by targeted evaluation of proteins that are related to our metabolomic results in SA1 using computer analysis to integrate the metabolomic and proteomic data for developing an early mechanistic disease profile. Specific Aim 3 will evaluate mitochondrial oxygen consumption rate (OCR) at P14, based on our preliminary data demonstrating a reduced OCR in rd10 mice as early as P16 and P18, suggesting that mitochondrial dysfunction is an early event in this model of RP. We will also test this hypothesis by performing evaluations of mitochondrial health such as mitochondrial dynamics (fusion and fission) and the integrity of the mitochondrial structure using Serial Block Face Scanning Electron Microscopy (SBFSEM). Abnormal mitochondrial structure or function identified in this aim will be integrated with the metabolomic and proteomic information from SA1 and SA2. For all specific aims, dark-reared and light-reared mice will be compared, since light is known to be an exacerbating factor for RP caused by the rd10 mutation. Based on a report that oxidative stress occurs at different time points and is differentially localized in male and female rd10 mice, we will also include gender as a variable. The ultimate goal of this proposal is to identify potential therapeutic targets in key pathways early in retinal degeneration.

摘要 视网膜色素变性(RP)是一种进行性视网膜变性，由70个基因突变中的至少3,000个突变引起 不同的基因导致视杆细胞死亡，随后是视锥细胞死亡，最终导致失明。虽然是氧化的 在RP中观察到应激和炎症，疾病进展的早期分子机制尚不清楚。 我们建议将rp的遗传小鼠模型rd10与野生型小鼠进行比较，以确定 利用广谱新策略建议治疗视网膜变性的治疗靶点 代谢组学与蛋白质组学和线粒体功能障碍分析相结合。RD10鼠标有一个 磷酸二酯酶6(PDE6)的β亚单位突变，它作为光的一部分，对cGMP进行水解性反应 光反应。该基因的突变会导致人类隐性RP。我们最近的非靶向代谢组学 研究发现，几种脱氧嘧啶和脱氧嘌呤的水平异常上升，以及一个关键 与野生型小鼠相比，rd10小鼠体内辅酶A合成途径中的代谢物。这些变化是 在P18观察，这是第一次检测到细胞死亡和光感受器功能下降。我们假设 在rd10小鼠体内观察到的代谢组的变化是由于相关的 蛋白质/酶。以确定在光感受器功能降低之前发生的代谢物的变化 检测到细胞死亡，我们建议分析较早时间点的小鼠，P14。在具体目标1中，我们将使用 P14的广谱(非靶向)和P14和P18的靶向代谢组学。在具体目标2中， 非靶向蛋白质组学将用于鉴定膜、可溶性和线粒体中的蛋白质/酶。 可能与疾病进程有关的部分。之后将对以下蛋白质进行有针对性的评估 与我们在SA1中的代谢结果有关，使用计算机分析来整合代谢和 用于开发早期机械性疾病概况的蛋白质组学数据。《特定目标3》将评估线粒体 P14的耗氧率(OCR)，基于我们的初步数据显示RD10的OCR降低 小鼠早在P16和P18，提示线粒体功能障碍是这一RP模型的早期事件。 我们还将通过评估线粒体的健康状况来检验这一假设 序列块人脸扫描的动态(融合和分裂)和线粒体结构的完整性 电子显微镜(SBFSEM)。在这一目标中发现的异常线粒体结构或功能将是 整合了SA1和SA2的代谢组和蛋白质组信息。对于所有特定的目标，黑暗中长大的 与轻饲养的小鼠进行比较，因为众所周知，光是由 RD10突变。根据一份报告，氧化应激发生在不同的时间点，并具有不同的局部性 在雄性和雌性rd10小鼠中，我们也将性别作为一个变量。这项提议的最终目标是 在视网膜变性的早期识别关键通路中的潜在治疗靶点。